The short version of ACTH(4-10) fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-03 and is reviewed periodically as new material appears.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
多数实验室与市售的 Semax 以冻干粉形式提供。冻干粉通常建议保存在 -20 °C 或更低温度下，同时避免光照与反复升温。短期运输有时采用冷藏条件，但长期保存仍以冷冻为主。分包操作应尽量减少开盖次数，以降低吸湿和微生物污染的风险。开封后若未一次用完，建议在干燥环境中密封并尽快放回低温储存。
溶液状态的稳定性明显低于冻干粉。肽类在水溶液中可能经历水解、氧化与聚集，其中甲硫氨酸和天冬酰胺等残基常是敏感位点。Semax 含有甲硫氨酸，因此氧化风险相对突出。工作液一般主张现配现用，或冷藏并在数日内用尽。缓冲液种类、pH 和离子强度都会影响降解速率，而关于最佳条件的公开数据并不统一。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Analog of an ACTH fragment |
| Amino acid length | Seven residues | Met-Glu-His-Phe-Pro-Gly-Pro |
| Origin | Moscow, 1980s | Institute of Molecular Genetics |
| Approved regions | Russia and some neighboring states | Not cleared in Western markets |
| Common trade names | Multiple national brands | Sold as a nasal formulation |
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
== Bibliography == Silva, Robert J. (2006). "Fermium, Mendelevium, Nobelium, and Lawrencium" (PDF). In Morss, Lester R.; Edelstein, Norman M.; Fuger, Jean (eds.). The Chemistry of the Actinide and Transactinide Elements. Vol. 3 (3rd ed.). Dordrecht: Springer. pp. 1621–1651. doi:10.1007/1-4020-3598-5_13. ISBN 978-1-4020-3555-5. Archived from the original (PDF) on 2010-07-17.
=== Reversible inhibitors === Traditionally, reversible enzyme inhibitors have been classified as competitive, uncompetitive, or non-competitive, according to their effects on KM and Vmax. These different effects result from the inhibitor binding to the enzyme E, to the enzyme–substrate complex ES, or to both, respectively. The division of these classes arises from a problem in their derivation and results in the need to use two different binding constants for one binding event. The binding of an inhibitor and its effect on the enzymatic activity are two distinctly different things, another problem the traditional equations fail to acknowledge. In noncompetitive inhibition the binding of the inhibitor results in 100% inhibition of the enzyme only, and fails to consider the possibility of anything in between. In noncompetitive inhibition, the inhibitor will bind to an enzyme at its allosteric site; therefore, the binding affinity, or inverse of KM, of the substrate with the enzyme will remain the same. On the other hand, the Vmax will decrease relative to an uninhibited enzyme. On a Lineweaver-Burk plot, the presence of a noncompetitive inhibitor is illustrated by a change in the y-intercept, defined as 1/Vmax. The x-intercept, defined as −1/KM, will remain the same. In competitive inhibition, the inhibitor will bind to an enzyme at the active site, competing with the substrate. As a result, the KM will increase and the Vmax will remain the same.
During his tenure with the X-Men, Wolverine becomes a mentor for Kitty Pryde and later on Jubilee. Logan again encounters Jean, who has been resurrected and re-joins the X-Men, leading to resumption of Logan's rivalry with Cyclops. He is able to recall some of the trauma he received from the Weapon X program and tries to investigate his past, although his memories remain unreliable because of brainwashing and false memory implants. He meets Maverick, another former participant in the Weapon X project, and discovers that he had previously worked together with Sabretooth in Team X. During a conflict, the supervillain Magneto forcibly removes the adamantium from Wolverine's skeleton. This massive trauma causes his healing factor to burn out and leads to the discovery that his claws are actually bone. Wolverine leaves the X-Men for a time, embarking on a series of adventures during which his healing factor returns. After his return to the X-Men, Cable's son Genesis kidnaps Wolverine and attempts to re-bond adamantium to his skeleton. This is unsuccessful and causes Wolverine's mutation to accelerate out of control. He degenerates physically and mentally into a more primitive, bestial state. Elektra helps him to recover his humanity. Eventually, the villain Apocalypse captures Wolverine, brainwashes him into becoming the Horseman of Death, and successfully re-bonds adamantium to his skeleton. Wolverine overcomes Apocalypse's programming and returns to the X-Men.
Sources: en.wikipedia.org
== History == Topiramate was discovered in 1979 by Bruce E. Maryanoff and Joseph F. Gardocki during their research work at McNeil Pharmaceuticals. Topiramate was first sold in 1996. Mylan Pharmaceuticals was granted final approval by the FDA for the sale of generic topiramate in the United States and the generic version was made available in September 2006. The last patent for topiramate in the U.S. was for use in children and expired on 28 February 2009.
Oxide mixtures: SiO2, Al2O3; MgO, SiO2; CaO, SiO2 Mounted bases: LiCO3 on silica; NR3, NH3, KNH2 on alumina; NaOH, KOH mounted on silica on alumina Inorganic chemicals: BaO, KNaCO3, BeO, MgO, CaO, KCN Anion exchange resins Charcoal that has been treated at 900 degrees Celsius or activates with N2O, NH3, ZnCl2-NH4Cl-CO2 Depending on a solid surface's ability to successfully form a conjugate base by absorbing an electrically neutral acid, basic strength of the surface is determined. The "number of basic sites per unit surface area of the solid" is used to express how much basic strength is found on a solid base catalyst. Scientists have developed two methods to measure the amount of basic sites: one, titration with benzoic acid using indicators and gaseous acid adsorption. A solid with enough basic strength will absorb an electrically neutral acidic indicator and cause the acidic indicator's color to change to the color of its conjugate base. When performing the gaseous acid adsorption method, nitric oxide is used. The basic sites are then determined by calculating the amount of carbon dioxide that is absorbed.
Extensive clinical research on almost exclusively LSD, mescaline, and psilocybin was conducted in the 1950s and 1960s. However, the amount of research done on psilocybin was nowhere near that of LSD. Psychedelics like LSD started to become more visible in the mainstream sphere in the 1950s. English writer Aldous Huxley tried mescaline, which he had obtained from English psychiatrist Humphry Osmond, in 1953, and described its effects in his 1954 book The Doors of Perception. British politician Christopher Mayhew tried mescaline in 1955 and this was reported on in the media. Osmond, in correspondence with Huxley, coined the term "psychedelic", meaning "mind-manifesting", in 1956. Al Hubbard, also known as the "Johnny Appleseed of LSD", played a key role in the spread of LSD in the 1950s and thereafter. Psychedelics became widely recreationally used by the public, for instance by the hippies, during the counterculture of the 1960s. Harvard psychologists Timothy Leary and Richard Alpert began studying LSD and psilocybin in the early 1960s and ended up being fired from the university in 1963. Sandoz Laboratories ceased distribution of Delysid in 1965. Psychedelics became controlled substances in the United States and internationally in the 1960s and 1970s. By the end of the 1960s, psychedelic clinical research throughout the world had largely ceased.
Sources: en.wikipedia.org
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.
It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.
Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.
一般不建议常温长期保存。多数说明指向 -20 °C 冷冻避光。常温运输通常被视为短期可接受，但会加快降解风险。